<DOC>
	<DOCNO>NCT00779259</DOCNO>
	<brief_summary>In prior vitro study use human hepatocytes quinine show induce activity Cytochrome p450 CYP 1A2 . The present study evaluate extent quinine sulfate-related induction enzyme effect pharmacokinetics theophylline , sensitive probe drug activity CYP 1A2 . It also evaluate effect single-dose theophylline pharmacokinetics steady-state quinine sulfate .</brief_summary>
	<brief_title>Drug - Drug Interaction Study Between Quinine Sulfate Theophylline</brief_title>
	<detailed_description>This study evaluate effect steady-state quinine sulfate pharmacokinetics single dose theophylline effect single dose theophylline pharmacokinetics steady-state quinine sulfate healthy adult male fast condition . In non-blinded , crossover study 24 normal , healthy , non-smoking , non-obese male volunteer serve control two cohort , one consist 8 subject one consist 16 subject . On Day 1 minimum overnight fast 10 hour , 8 study participant cohort 1 receive single oral dose theophylline ( 300 mg immediate-release oral solution 80 mg/ 15 ml concentration ) . After 4 day washout period , 8 subject receive 648 mg dose quinine sulfate ( 2 x 324 mg capsule ) every 8 hour ( dose 7 , 3 pm 11 pm daily ) begin 3 pm dose Day 5 continue morning dose Day 12 . The 8 subject co-administered single oral dos theophylline ( 300 mg immediate-release oral solution 80 mg/ 15 ml concentration ) quinine sulfate ( 2 x 324 mg capsule ) 7 Day 12 . Cohort 2 dosed basis safety finding Cohort 1 . If ≥ 50 % volunteer cohort 1 tolerate 648 mg dose quinine sulfate , second cohort 16 volunteer receive dose quinine sulfate reduce 648 mg 324 mg every 8 hour . In cohort serial pharmacokinetic blood sample draw time sufficient adequately define pharmacokinetics theophylline quinine . Blood sample measurement theophylline plasma concentration collect Days 1 12 prior dose 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 12 , 16 , 24 , 36 48 hour post-dose . Blood sample measurement quinine sulfate plasma concentration collect Day 11 prior morning dose 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 hour post dose Day 12 prior dose 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 8 hour post-dose . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout participation study adverse reaction study drug and/or procedure . Vital sign ( sit blood pressure pulse ) measure prior morning dose 1 , 2 4 hour administration morning dose Days 1 , 11 12 . On Day 5 , sit blood pressure pulse measure prior afternoon dose 1 , 2 4 hour administration afternoon dose . ECGs collect pre-dose 4 hour morning dose study Days 1 , 5 , 11 12 . All adverse event whether elicited query , spontaneously report observed clinic staff evaluate investigator report subject 's case report form .</detailed_description>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>Medically healthy nonsmoking , nonobese ( ≥ 55kg within 15 % ideal body weight ) adult male volunteer 1845 year age Subjects history presence glucose 6 phosphate dehydrogenase deficiency , myasthenia gravis , optic neuritis , glaucoma significant cardiovascular disease ( include hypotension , bradycardia EKG abnormality ) , pulmonary , hepatic , gallbladder biliary tract , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease active sexually transmitted disease Subjects significant blood loss prior 56 day , plasma donation within 7 day , hemoglobin &lt; 12.0 g/dl participate another clinical trial within prior 30 day Subjects recent ( 2year ) history evidence alcoholism drug abuse Subjects use drug substance know inhibit induce cytochrome P450 ( CYP ) enzymes and/or Pglycoprotein within 30 day prior first dose throughout study Subjects test positive screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) . Subjects pregnant lactate hypersensitivity quinine sulfate , mefloquine , quinidine hypersensitivity theophylline aminophylline .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>quinine sulfate</keyword>
	<keyword>theophylline</keyword>
	<keyword>drug interaction</keyword>
	<keyword>cytochrome p450</keyword>
	<keyword>human</keyword>
	<keyword>male</keyword>
	<keyword>adult</keyword>
</DOC>